Akorn Short ratio
Cos'è Short ratio di Akorn?
Short ratio di Akorn, Inc. è 0.49
Qual è la definizione di Short ratio?
Short ratio è il numero di azioni vendute breve diviso per il volume medio giornaliero.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Short ratio di aziende nel Health Care settore su OTC rispetto a Akorn
Cosa fa Akorn?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Aziende con short ratio simili a Akorn
- Acorn International Inc ha Short ratio di 0.48
- Calyx Ventures ha Short ratio di 0.48
- Condor Hospitality Trust Inc ha Short ratio di 0.48
- Vivaldi Opportunities Fund ha Short ratio di 0.48
- HTG Molecular Diagnostics Inc ha Short ratio di 0.48
- Otelco Inc ha Short ratio di 0.48
- Akorn ha Short ratio di 0.49
- Axovant Gene Therapies ha Short ratio di 0.50
- Fieldex Exploration ha Short ratio di 0.50
- CMC Metals ha Short ratio di 0.50
- Peeks Social ha Short ratio di 0.50
- Xortx Therapeutics Inc ha Short ratio di 0.50
- Visionary Gold ha Short ratio di 0.50